Last reviewed · How we verify
GSK1265744 Reference formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK1265744 Reference formulation (GSK1265744 Reference formulation) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK1265744 Reference formulation TARGET | GSK1265744 Reference formulation | ViiV Healthcare | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK1265744 Reference formulation CI watch — RSS
- GSK1265744 Reference formulation CI watch — Atom
- GSK1265744 Reference formulation CI watch — JSON
- GSK1265744 Reference formulation alone — RSS
Cite this brief
Drug Landscape (2026). GSK1265744 Reference formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1265744-reference-formulation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab